Clinical and histopathological spectrum of toxic erythema of chemotherapy in patients who have undergone allogenic hematopoietic cell transplantation

Manrup K. Hunjan, Somaira Nowsheen, Alvaro J. Rodriguez, Shahrukh K. Hashmi, Alina G. Bridges, Julia Lehman, Rokea El-Azhary

Research output: Contribution to journalArticle


Objective/Background: Toxic erythema of chemotherapy (TEC) is a well-recognized adverse cutaneous reaction to chemotherapy. Similar to many skin diseases, the clinical presentations may vary. Our objective is to expand on the typical and atypical clinical and histopathological presentations of TEC. Methods: Forty-two patients with a diagnosis of TEC were included from 500 patients who had undergone an allogenic hematopoietic stem cell transplant. Relevant information and demonstrative photos and pathology were selected. Results: Classic clinical presentations included hand and foot erythema and dysesthesias; atypical presentations included facial involvement, hyperpigmentation, dermatomyositis-like, and erythroderma associated with capillary leak syndrome. Conclusion: The diagnosis of TEC should be considered after a correlation of clinical and histological findings in conjunction with a timeline of chemotherapy administration. Suggested criteria for the diagnosis of TEC may be helpful to dermatologists and clinicians when caring for these patients.

Original languageEnglish (US)
JournalHematology/ Oncology and Stem Cell Therapy
StateAccepted/In press - Jan 1 2018



  • Cancer
  • Capillary leak syndrome (CLS)
  • Chemotherapy
  • Stem cell transplant
  • Toxic epidermal necrolysis
  • Toxic erythema of chemotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this